Skip to main navigation
Skip to search
Skip to main content
WashU Medicine Research Profiles Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Strength of the evidence: Adjuvant therapy for resected pancreatic cancer
Vincent J. Picozzi
, Peter W.T. Pisters
, Selwyn M. Vickers
, Steven M. Strasberg
Department of Surgery
Research output
:
Contribution to journal
›
Article
›
peer-review
26
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Strength of the evidence: Adjuvant therapy for resected pancreatic cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Randomized Trial
100%
Pancreatic Cancer
100%
Adjuvant Therapy
100%
Adjuvant Chemotherapy
100%
Resectable Pancreatic Cancer
100%
Gemcitabine
50%
5-year Survival
50%
5-fluorouracil (5-FU)
50%
Oncology
50%
Adjuvant Chemoradiation
50%
Pancreas Cancer
50%
Cancer 2
50%
EORTC
50%
Pancreaticoduodenectomy
50%
Significant Region
50%
Methodological Differences
50%
World Opinion
50%
ESPAC
50%
Medicine and Dentistry
Adjuvant Therapy
100%
Pancreas Cancer
100%
Adjuvant Chemotherapy
50%
Oncology
25%
Chemoradiotherapy
25%
Gemcitabine
25%
Pancreaticoduodenectomy
25%